💰 Financial Performance

Revenue Growth by Segment

The company reported a turnover of INR 159.47 Cr in FY 2024-25, representing a 19.15% decrease from INR 197.24 Cr in FY 2023-24. Revenue is primarily driven by the anti-ulcerative segment (Prazoles), which accounts for the majority of sales. Historical 5-year sales growth was 20% as of FY 2019-20.

Geographic Revenue Split

Exports contributed approximately 27-28% of total sales in FY 2024-25, with the remaining 72-73% derived from the domestic Indian market. The company currently serves 85 clients across 48 countries, with a target to reach 120 clients in 60 countries within three years.

Profitability Margins

Net Profit Margin declined to -0.81% in FY 2024-25. Return on Net Worth dropped to -1.84% in FY 2024-25 from 3.08% in FY 2023-24. Historically, the company maintained a PAT of INR 10.89 Cr (6.4% margin) in FY 2019-20.

EBITDA Margin

Operating margins significantly moderated to 1.2% in FY 2023 from 12.9% in FY 2021 due to high raw material costs. Margins improved to approximately 6% in Q1 FY 2024 and were projected to reach 6-7% for the full year FY 2024 based on better product mix.

Capital Expenditure

The company undertook capital expenditure of INR 15 Cr in FY 2024-25 for a new production block, following an investment of INR 3.23 Cr in FY 2023-24. Total planned expansion includes a 3X capacity increase supported by EC clearance.

Credit Rating & Borrowing

ICRA reaffirmed [ICRA] B+ (Stable) and [ICRA] A4 ratings in August 2023 but subsequently withdrew them in July 2024 at the company's request. Previous ratings from Brickwork in FY 2019-20 were BWR BBB-/Stable for term loans.

⚙️ Operational Drivers

Raw Materials

Key raw materials include intermediates for Prazole APIs, Chloro compounds, and Benzimadizole. Specific chemical names are not fully listed, but they represent a significant portion of the cost structure, with procurement heavily reliant on external suppliers.

Import Sources

China is the primary source for raw material procurement, accounting for approximately 70-80% of total requirements. This creates high dependency on Chinese supply chains and vulnerability to cross-border trade dynamics.

Key Suppliers

Not disclosed in available documents, though the company maintains established relationships with Chinese suppliers for 70-80% of its procurement needs.

Capacity Expansion

Current installed production capacity is 820 MTPA at the Aroor village facility. The company has received EC clearance for a 3X expansion in capacity to support future growth and R&D capabilities.

Raw Material Costs

Raw material costs are a major driver of margin volatility; operating margins crashed from 12.9% to 1.2% in FY 2023 because unfavorable raw material costs could not be passed on to customers due to intense competition.

Manufacturing Efficiency

The company is currently operating at a healthy capacity utilization level of 80-90% for its existing product portfolio. The plant is USFDA, WHO-GMP, and ISO certified.

Logistics & Distribution

The company distributes to 48 countries globally, with exports making up 27-28% of sales. Logistics are managed to ensure drug efficacy and mitigate contamination risks.

📈 Strategic Growth

Expected Growth Rate

20%

Growth Strategy

Growth will be achieved through a 3X capacity expansion, entering the Phytochemical-immune segment with Curcumin and Piperine, and registering products in new markets including China (2 products), Korea (2 products), and Russia (5 products).

Products & Services

Active Pharmaceutical Ingredients (APIs) and Intermediates including Omeprazole, Esomeprazole, Fenofibrate, Pantoprazole, Itraconazole, Rabeprazole, Chloro compound, and Benzimadizole.

Brand Portfolio

Everest Organics Limited operates primarily as a B2B API manufacturer; specific consumer brand names are not applicable.

New Products/Services

New launches include Curcumin and Piperine Energy Immune Boosters. Six additional products are in advanced stages of regulatory approval to diversify the portfolio beyond the Prazole segment.

Market Expansion

Targeting expansion from 48 to 60 countries and increasing the client base from 85 to 120 within three years. Exploring regulated market opportunities in the US and EU.

Market Share & Ranking

The company describes itself as a global market leader in the Prazole segment, specifically for Omeprazole and Pantoprazole.

🌍 External Factors

Industry Trends

The Indian pharma market is projected to reach USD 130 billion by 2030. Trends include a shift toward chronic therapy (cardiac, oncology) and increased digital health integration via the Ayushman Bharat Digital Mission.

Competitive Landscape

Intense competition from both domestic and international API manufacturers, particularly in mature segments like anti-ulceratives, which pressures operating margins.

Competitive Moat

Moat is based on a 30-year track record in advanced chemistry, USFDA approval (received June 2017), and a 33-acre manufacturing site. Sustainability is challenged by environmental compliance issues.

Macro Economic Sensitivity

Sensitive to global demand-supply conditions and Indian GDP growth. Rising middle-class healthcare spending in India supports domestic demand.

Consumer Behavior

Increasing urbanization and disposable income in India are driving higher healthcare spending and demand for OTC and chronic therapy medications.

Geopolitical Risks

Trade relations with China are critical due to 70-80% procurement dependency. Increasing competition from low-cost manufacturing countries adds to the risk landscape.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by USFDA, WHO-GMP, and TSPCB guidelines. Regulatory approvals are secured for 3 products, with 6 more in progress and multiple registrations pending in China, Korea, and Russia.

Environmental Compliance

The company faces significant risks regarding TSPCB (Telangana State Pollution Control Board) norms. Auditors noted production has exceeded approved thresholds, which could lead to plant closure as seen in the past.

Legal Contingencies

The company's auditor provided a qualified opinion regarding revenue recognition (not in line with IND-AS 115), production exceeding approved limits, and the absence of actuarial assessment for gratuity liability.

⚠️ Risk Analysis

Key Uncertainties

Non-compliance with pollution control guidelines (TSPCB) and potential disruption of operations. High dependency on Chinese suppliers (70-80%) for raw materials.

Geographic Concentration Risk

Approximately 72-73% of revenue is concentrated in the Indian domestic market, while 27-28% is spread across 48 export countries.

Third Party Dependencies

Critical dependency on Chinese vendors for 70-80% of raw material procurement, creating a single-point-of-failure risk for the supply chain.

Technology Obsolescence Risk

The company is mitigating technology risks by investing INR 15 Cr in a new production block and upgrading R&D for phytochemicals and new-age therapies.

Credit & Counterparty Risk

Receivables quality is a monitorable factor; the auditor highlighted revenue recognition issues where ownership transfer and risks had not fully occurred at the time of reporting.